John Raymond Zalcberg, PhD, MBBS, discusses the rationale for intra-patient dose escalation with ripretinib, as was examined in the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.
John Zalcberg, PhD, OAM
Advertisement
Articles by John Zalcberg, PhD, OAM
John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.
John Zalcberg, PhD, OAM, discusses the approval of avapritinib in gastrointestinal stromal tumor.
John Zalcberg, PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor.
John Zalcberg, PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor.
John Zalcberg, PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.
Advertisement
Latest Updated Articles
Dr. Zalcberg on Updated Results from the Phase 3 INVICTUS Study in Advanced GISTPublished: September 20th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5